Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Eastman Chemical Company’s ( EMN - Analyst Report ) impending purchase of Missouri-based chemical company Solutia Inc. ( ) has been cleared by the latter’s shareholders. This follows the approval of the deal by the European Commission in May 2012. Roughly 99% of the shareholders, who voted in a special meeting, approved the deal.
With all regulatory conditions have been met, the transaction now remains subject to the satisfaction or waiver of certain customary closing conditions. The acquisition is expected to consummate in the first week of July.
Eastman, in January 2012, landed a cash and stock deal worth $3.4 billion to acquire Solutia, a global leader in performance materials and specialty chemicals. The move is a part of the company’s expansion strategy. Per the agreement, Solutia stockholders will receive $22.00 in cash and 0.12 shares of Eastman common stock for each Solutia share.
Solutia registered around 30% of sales in 2011 from Asia-Pacific. Eastman believes that the takeover will help it to expand its foothold in China. The company envisions the transaction to immediately add to its earnings.
Annual cost synergies are expected to be roughly $100 million by 2013. Moreover, Eastman expects to realize significant tax benefits from the acquisition. It also recognizes the potential for meaningful revenue synergies by leveraging both companies’ technology and business capabilities and overlapping end-markets, particularly in automotive and architecture.
Eastman's diversified chemical portfolio, along with its integrated and diverse downstream businesses, is driving earnings. The company benefits from business restructuring and cost-cutting measures. It has sold unprofitable units and closed down the poorly performing ones.
Eastman expects the global economy to grow slowly while volatility in raw material and energy costs to subside in the near-term. The company expects earnings to be roughly $5.30 a share in 2012. It expects to benefit from the increased capacity additions as well as the Solutia acquisition.
Eastman, which competes with The Dow Chemical Company ( DOW - Analyst Report ) and E. I. du Pont de Nemours and Company ( DD - Analyst Report ) , holds a short-term Zacks #2 Rank (Buy). We currently have a long-term Outperform recommendation on the stock.
Read the full reports :
Analyst Report on DD
Analyst Report on DOW
Analyst Report on EMN